About the group

Human immunodeficiency virus (HIV), tuberculosis (TB), Hepatitis B (HBV), sepsis, influenza and COVID-19 are all globally dominant infections with increased or dysregulated inflammation important for the outcome of the disease. 

Studies of new treatment strategies and prognostic biomarkers for disease progression and treatment efficacy are needed in order to develop and evaluate personalized treatments, but require a good biological understanding of the disease mechanisms.

Focus of research

We aim to strengthen clinical research in collaboration with users and industry. Through translational research, we will contribute to increase knowledge about immunopathogenesis, biomarkers and new treatments for chronic and acute infections.

We work interdisciplinary and in collaboration with national and international research networks. Our research will contribute to develop personalized medicine for our patients and a research platform for future pandemics.

Our research includes

  • Preclinical studies of biobanks collected from our hospitalized patients
  • Clinical intervention studies of vaccines and new treatment strategies
  • Quality register studies of HIV, TB, Hepatitis B, Sepsis and COVID-19
  • Clinical partner in externally initiated projects and assigned research

Projects

Our main research areas are:

  • Tuberculosis
  • HIV
  • Hepatitis B
  • Sepsis
  • Covid-19

For more detailed overview see our projects page.

Cooperation

Her is an overview over our collaborators.

National

  • University of Oslo (UiO):
    • Institute of Clinical Medicine: Department of Immunology
    • Centre for Global Health
    • K.G. Jebsen Centre for Influenza Vaccine Research
    • Turning the tide of antimicrobial resistance (TTA) 
    • Oslo HIV Research Network
    • Department of Biostatistics (sepsis)
  • Oslo University Hospital (OUH):
    • Competence center for imported and tropical diseases
    • Department of Acute Medicine
    • Department of Gastroenterology
    • Pulmonary department
    • Department of Medical Biochemistry
    • Department of Microbiology
    • Norwegian PSC Research Centre
    • Section for infectious diseases
    • Department of Dermatology (Rikshospitalet) 
  • University of Bergen: Centre for International Health, Department of Clinical Science
  • OsloMet: Faculty of Health Sciences (HV)
  • NTNU and St. Olavs Hospital: Department of Clinical and Molecular Medicine
  • University Hospital of North Norway: NORM - Norsk overvåkingssystem for antibiotikaresistens hos mikrober
  • Norwegian Institute of Public Health, Oslo 
  • Vestfold Hospital
  • Akershus University Hospital

International

  • Statens Seruminstitutt, København (TB)
  • Hvidøvre Hospital and University of Copenhagen, Denmark (HBV)
  • Rikshospitalet, København (HIV/TB)
  • Karolinska Instituttet, Stockholm (HBV)
  • Stellenbosch University Immunology Research Group, University of Stellenbosch, Sør-Afrika (TB) 
  • Unitat de Tuberculosi Experimental, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona, Spania (TB)
  • Universitetet i Leiden (TB)
  • EUROSIDA (europeisk HIV nettverk)
  • TBnet (europeisk TB nettverk)
  • Amsterdam University Medical Center (sepsis)
  • University of Edinburgh (sepsis)